Yes, elderly patients who have only received PPSV23 should receive PCV20
According to the 2023 ACIP guidelines, all adults who previously received PPSV23 only should receive a single dose of either PCV20 or PCV15 at least 1 year after their last PPSV23 dose 1. This recommendation applies regardless of age and represents a significant update to pneumococcal vaccination strategy.
Rationale for the Recommendation
The recommendation is based on several key factors:
Superior immunologic properties: Conjugate vaccines (PCVs) generate stronger and more durable immune responses compared to PPSV23, including T-cell dependent immunity and immunologic memory 1
Limited duration of PPSV23 protection: PPSV23 provides only temporary protection that wanes over time, without generating robust immunologic memory 1
Expanded serotype coverage: PCV20 includes 7 additional serotypes beyond PCV13, providing broader protection against current circulating pneumococcal strains 1
Simplified vaccination schedule: A single dose of PCV20 eliminates the need for additional PPSV23 doses 1
Timing and Administration
Wait at least 1 year after the last PPSV23 dose before administering PCV20 1. This interval is critical because:
- Giving a conjugate vaccine too soon after PPSV23 can cause immune interference or hyporesponsiveness, reducing the effectiveness of the PCV 2
- The 1-year interval allows for optimal immune response to the conjugate vaccine 2
Special Populations
For patients with immunocompromising conditions, CSF leak, or cochlear implant, the minimum interval can be shortened to 8 weeks to minimize their time at risk for invasive pneumococcal disease 1. However, the preferred interval remains 1 year when feasible.
Alternative Option
If PCV20 is unavailable, patients can receive PCV15 followed by PPSV23 at least 1 year later (or 8 weeks for high-risk patients) 1. However, when PCV15 or PCV20 is used in adults who previously received PPSV23, no additional PPSV23 dose is needed 1.
Clinical Evidence
Studies demonstrate that PCV20 is well-tolerated and produces robust immune responses, including opsonophagocytic antibody responses, in adults ≥65 years previously vaccinated with PPSV23 3, 4. The safety profile is comparable to PCV13 and PPSV23 3.
Common Pitfalls to Avoid
- Don't administer PCV20 too soon: Respect the 1-year interval to avoid immune interference
- Don't give additional PPSV23: Once PCV20 is administered, no further PPSV23 doses are indicated 1
- Don't assume PPSV23 alone is sufficient: The limited duration of protection and lack of immunologic memory make additional vaccination with a conjugate vaccine beneficial
Updated 2024 Guidance
As of October 2024, ACIP has expanded recommendations to include all adults ≥50 years (previously ≥65 years), making PCV20 vaccination even more broadly indicated 5. This further supports vaccinating elderly patients who have only received PPSV23.